CION Ameerpet
Being told your cancer started in the fallopian tube sounds like a rare and unfamiliar diagnosis. It is neither. Fallopian tube cancer is staged, treated and followed up as ovarian cancer — the same protocol, the same chemotherapy, the same testing. What changed is not your treatment, but our understanding of where this disease begins.
Fallopian tube cancer is a malignant tumour that begins in one of the two tubes running from the ovaries to the uterus. In the great majority of cases it is a high-grade serous carcinoma, and it starts at the fimbrial end — the fringed opening that sits closest to the ovary. That single anatomical detail explains most of what follows on this page.
For most of the last century tubal carcinoma was recorded as one of the rarest gynaecological cancers. Then pathologists began sectioning the entire tube rather than sampling it, and found early cancerous change there in specimens that had been removed for other reasons. Much of what had been labelled ovarian cancer had, in fact, begun in the tube. The rarity was partly a matter of where nobody had thought to look closely.
The practical consequence for you is reassuring rather than alarming. Because tubal, ovarian and peritoneal high-grade serous carcinoma are now understood as one disease, your care runs on the ovarian cancer pathway that oncology teams use every week — the same staging system, the same chemotherapy, the same genetic testing and the same follow-up. A rare-sounding label does not mean an experimental or unfamiliar treatment plan.
The fringed opening of the tube nearest the ovary, which is where the earliest precursor lesions are found.
The same subtype that accounts for most ovarian cancer. See high-grade serous carcinoma.
Many cancers once recorded as ovarian are now correctly assigned to the tube. The treatment did not change.
Until 2014, ovarian, fallopian tube and peritoneal cancers were staged as three separate diseases. FIGO then replaced all three systems with a single staging classification covering the ovary, the fallopian tube and the peritoneum together, and the WHO classification treats high-grade serous carcinoma of these three sites as one entity. The reason was pathological rather than administrative: when the whole tube was sliced thinly and examined in full — the SEE-FIM protocol, developed for risk-reducing surgery specimens in BRCA carriers — early lesions called STIC, serous tubal intraepithelial carcinoma, kept turning up at the fimbrial end. Where the disease starts turned out to matter far less than what it is. Source: FIGO Committee on Gynecologic Oncology staging classification (2014); WHO Classification of Tumours, Female Genital Tumours.
These are the questions women ask in the days after the report arrives. The short version: the site on your report describes where the disease began, not a different illness or a different plan.
| The question | What is actually the case | Why it matters to you |
|---|---|---|
| Is this a different cancer from ovarian cancer? | No. High-grade serous carcinoma of the tube, ovary and peritoneum is classified as a single entity. | Your treatment protocol is the ovarian one, used by oncology teams routinely. |
| Is it staged differently? | No. FIGO has staged ovarian, tubal and peritoneal carcinoma on one system since 2014. | Stage I to IV means exactly what it means in ovarian cancer, and drives the same decisions. |
| Why does my report name the tube? | The pathologist assigns the primary site where the bulk of the tumour, or a STIC lesion, sits. | It is a statement about origin. It does not, by itself, change your outlook. |
| Does chemotherapy work on it? | It is treated with platinum-based chemotherapy and generally behaves as high-grade serous disease does. | The most useful practical fact you can hold on to: this is a chemo-sensitive disease family. |
| Does BRCA testing apply to me? | Yes. Tubal carcinoma carries a strong association with BRCA1 and BRCA2, whatever your family history. | The result guides maintenance therapy for you, and risk assessment for your relatives. |
| What is primary peritoneal cancer then? | The third site in the same family — diagnosed when the tumour bulk sits on the peritoneal lining. | Same staging, same treatment. See primary peritoneal cancer. |
*If your report and your discharge summary use different words for the same cancer — tubal in one, ovarian in the other — that is usually this reclassification showing through rather than an error. Ask your oncologist to confirm it at your next visit.
Tubal cancer symptoms overlap almost completely with ovarian cancer symptoms, with one or two additions that are classically described but genuinely uncommon.
Persistent bloating, feeling full quickly, pelvic or abdominal pain, and new urinary urgency or frequency. What matters is the pattern rather than any single symptom: new, present on most days, not settling, and continuing for weeks rather than fluctuating with meals or your cycle.
None of these is specific to the tube, and none of them announces cancer on its own. They are ordinary symptoms that become meaningful when they are new, persistent and progressive together.
A profuse watery vaginal discharge, sometimes blood-stained, with pelvic pain and a pelvic mass is the classical description of tubal carcinoma. In practice it is uncommon, and most women with fallopian tube cancer never experience it — which is exactly why it should not be waited for.
Bleeding after the menopause, or new bleeding between periods, has many causes and is far more often due to something in the uterus or cervix than in the tube. It still warrants assessment every time, without exception.
This has to be said plainly, because it is the single most common misunderstanding. There is no effective screening for ovarian or fallopian tube cancer in any group of women. Regular CA-125 blood tests and ultrasound scans have been studied carefully and do not reliably find this disease early enough to change outcomes, and that remains true for women carrying a BRCA variant.
For a woman at high inherited risk, the intervention that does reduce risk is risk-reducing surgery to remove the tubes and ovaries, discussed and timed with a genetic counsellor. Surveillance is a way of watching, not a way of protecting, and it should never be presented as the latter.
Most often through the same route as ovarian cancer: a pelvic ultrasound showing a mass or free fluid, a raised CA-125, and a CT scan of the chest, abdomen and pelvis that maps the extent of disease. The diagnosis itself is made on tissue, not on a scan or a blood test.
A proportion of tubal cancers are found unexpectedly — in a tube removed during surgery for something else, or in the specimen after risk-reducing surgery in a BRCA carrier. Finding it that way is not a bad outcome. It is generally how this disease gets caught early.
The tube is sectioned thinly and examined in full, with particular attention to the fimbrial end. A STIC lesion there, or the bulk of the tumour sitting in the tube, points to a tubal primary. Immunohistochemistry confirms the serous subtype, and TP53 abnormality is characteristic of high-grade serous disease.
Where the ovaries, tube and peritoneum are all involved, assigning a single site of origin can be genuinely difficult, and different pathologists may word it differently. This does not hold up treatment, because the protocol is the same for all three.
A staging CT if it has not already been done, a baseline CA-125 to measure response against, and germline BRCA1 and BRCA2 testing with tumour HRD testing. Genetic testing here is not only about your relatives — it determines whether maintenance therapy is an option for you.
Genetic counselling, BRCA testing and HRD testing are delivered in-house at CION. Every case is reviewed at a tumour board before a plan is set, rather than decided by one clinician alone.
These come up in almost every second-opinion consultation, and are frequently not covered unless you ask directly.
Ask for the subtype, the grade, and whether a STIC lesion was described. That wording sets the whole treatment path.
For tubal carcinoma the answer should be yes. If the plan sounds unfamiliar, ask what makes your case different.
Both are offered regardless of family history, and both decide whether maintenance therapy applies to you.
PARP-inhibitor-class treatment after chemotherapy, where DNA repair is impaired. Raise it if nobody has mentioned it.
Staging and debulking outcomes are better with a specialist gynaecologic-oncology surgeon. A fair question to ask directly.
Multidisciplinary review before the plan is set is standard practice, not an optional extra.
If your plan makes no mention of BRCA or HRD testing, treat that as a gap worth raising rather than assuming it was considered and ruled out.
Fallopian tube cancer follows the ovarian cancer protocol from the first scan to the last follow-up. Bring your pathology report to a free 45-minute consultation and have someone walk you through exactly what it says.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Chemotherapy, maintenance therapy and BRCA and HRD testing are delivered in-house at CION — see how ovarian cancer treatment is organised.
The sequence below is the ovarian cancer pathway, because that is what tubal carcinoma is treated on. Where it runs in-house at CION and where it is coordinated elsewhere is stated at each step.
The operation removes the tubes, ovaries and uterus, samples the peritoneum and omentum, and takes out all visible disease. How completely that is achieved is one of the strongest influences on outcome in advanced disease, which is why the surgeon's specialty matters. At CION this surgery is coordinated with specialist gynaecologic-oncology partner centres and may be billed there — we would rather say that plainly upfront than have you discover it later.
Platinum-based chemotherapy is the backbone of treatment, and high-grade serous disease of the tube is typically responsive to it. Response is often visible early, through a falling CA-125 and reducing abdominal fluid. Chemotherapy is delivered in-house at CION across more than 35 centres in Telangana and Andhra Pradesh, so treatment can continue near where you live rather than requiring long journeys while you are unwell.
Where imaging suggests all visible disease can be removed at the outset, surgery comes first and chemotherapy follows. Where disease is too extensive for that, chemotherapy is given first to shrink it, with surgery in the middle of the course. Neither route is a lesser option — the CT scan and the extent of disease largely decide which one you are on. See how ovarian cancer treatment is organised.
Germline BRCA testing is offered to essentially every woman with tubal, ovarian or peritoneal carcinoma, whatever her family history, because the result guides her own treatment. Tumour HRD testing asks a related question about the cancer's DNA repair. Both, along with genetic counselling, are delivered in-house at CION rather than arranged elsewhere and waited on.
After first-line chemotherapy, maintenance therapy aims to extend the period before the disease returns. PARP-inhibitor-class treatment is the principal option, and it works best where DNA repair is impaired — which is what the BRCA and HRD results tell you. Maintenance therapy is delivered in-house at CION. If it has not been discussed, ask whether it applies to you.
Follow-up combines symptom review, examination and CA-125, which is genuinely informative in this subtype because it is usually raised at diagnosis. If the disease does return, it remains treatable — the interval since platinum chemotherapy finished is what shapes the options, and many women manage recurrent disease over years rather than facing a single decisive event.
*Every treatment decision here is made against your stage, your pathology and your general health. This page describes the standard pathway, not a plan for any individual.
The most useful thing a first consultation does after this diagnosis is unhurried translation — of the pathology report, the staging, and what the plan on the discharge summary actually commits you to. Your first consultation at CION is free and runs to about 45 minutes. Bring the pathology report and any imaging discs you have; they answer more questions than any conversation without them can.
What is delivered in-house at CION is the medical oncology side: chemotherapy and PARP-inhibitor-class maintenance therapy across 35+ centres in Telangana and Andhra Pradesh, along with genetic counselling and BRCA and HRD testing, nutrition support and long-term follow-up. Staging and debulking surgery is coordinated with specialist gynaecologic-oncology partner centres and may be billed there, as are HIPEC and PET-CT where they are indicated. Outcomes for this surgery are better in specialist hands, which is why it is arranged that way rather than kept in-house.
On survival figures, one honest note. CION publishes its own one-year survival alongside the national figure so the comparison is visible rather than implied: 81.0% of CION ovarian cancer patients are alive at one year, against a national figure of 73.7%. That covers the whole treated population — ovarian, tubal and peritoneal disease is counted together — and it is a one-year figure, not a cure rate and not a prediction for you. Published survival numbers for a diagnosis as specifically labelled as tubal carcinoma mislead badly in any case: they are historical, they average across every stage and substage, and they mix women who had complete surgery with women who did not. Your own outlook is a conversation with your oncologist, who can speak to your actual situation.
Free, unhurried, and long enough to go through the pathology report line by line rather than summarising it.
BRCA and HRD testing, chemotherapy and maintenance therapy all delivered in-house, with no weeks lost between steps.
Medical oncology, imaging and pathology review the case together before any plan is settled.
Staging and debulking at specialist gynaecologic-oncology partner centres, where it may also be billed.
*One-year survival rates. CION figures reflect CION's treated patient population; national figures are drawn from published Indian cancer registry data. Survival statistics describe groups rather than individuals — discuss your own prognosis with your treating oncologist.
Fallopian tube cancer is a malignant tumour that begins in one of the two tubes running from the ovaries to the uterus. In the great majority of cases it is a high-grade serous carcinoma, and it starts at the fimbrial end — the fringed opening nearest the ovary. It was recorded for decades as one of the rarest gynaecological cancers, until pathologists began sectioning the whole tube rather than sampling it and found that many cancers previously labelled ovarian had in fact begun there. Under the current classification, high-grade serous carcinoma of the tube, the ovary and the peritoneum is treated as one disease, and the treatment pathway is the ovarian cancer one.
For practical purposes, yes. They are classified as a single entity when the subtype is high-grade serous, which is what tubal carcinoma almost always is. FIGO has staged ovarian, fallopian tube and peritoneal carcinoma on one system since 2014, so stage I to IV means the same thing across all three. The surgery is the same operation, the chemotherapy is the same platinum-based treatment, the genetic testing is the same, and the follow-up is the same. The site named on your report describes where the disease is thought to have begun. It is not a different illness, and on its own it does not change what happens next.
Tubal cancer symptoms overlap almost entirely with ovarian cancer symptoms: persistent bloating, feeling full quickly, pelvic or abdominal pain, and new urinary urgency or frequency. The pattern matters more than any single symptom — new, present on most days, not settling, and continuing for weeks. There are two additions described classically for the tube: a profuse watery, sometimes blood-stained vaginal discharge, and abnormal or postmenopausal bleeding. Both are genuinely uncommon, and most women with fallopian tube cancer never experience the watery discharge at all, so it should never be waited for as a confirmation. Any bleeding after the menopause warrants assessment regardless of the cause.
Usually along the same route as ovarian cancer. A pelvic ultrasound shows a mass or free fluid, CA-125 is often raised, and a CT scan of the chest, abdomen and pelvis maps the extent of disease. The diagnosis itself is made on tissue rather than on any scan or blood test. The pathologist assigns the tube as the primary site when the bulk of the tumour sits there, or when an early precursor lesion called STIC is found at the fimbrial end during full sectioning of the tube. A proportion of these cancers are found unexpectedly, in a tube removed during other surgery or after risk-reducing surgery in a woman carrying a BRCA variant.
No, and this is worth stating plainly because it is so widely misunderstood. There is no effective screening for ovarian or fallopian tube cancer in any group of women. Regular CA-125 tests and ultrasound scans have been studied carefully and do not find the disease early enough to change outcomes — and that remains true for women carrying a BRCA1 or BRCA2 variant, where the misunderstanding causes the most harm. For women at high inherited risk, what does reduce risk is surgery to remove the tubes and ovaries, timed and discussed with a genetic counsellor. Surveillance is a way of watching, not a way of protecting, and nobody should be told otherwise.
The first consultation is free and runs to about 45 minutes — bring your pathology report and any imaging. Chemotherapy and PARP-inhibitor-class maintenance therapy are delivered in-house at CION across more than 35 centres in Telangana and Andhra Pradesh, and so are genetic counselling and BRCA and HRD testing, which is what determines whether maintenance therapy applies to you. Staging and debulking surgery is coordinated with specialist gynaecologic-oncology partner centres and may be billed there, as are HIPEC and PET-CT where indicated. Every case that raises a question is reviewed at a tumour board rather than decided by one clinician alone.